BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23462324)

  • 1. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
    Hubner RA; Worsnop F; Cunningham D; Chau I
    Pancreas; 2013 Apr; 42(3):511-5. PubMed ID: 23462324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
    Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
    J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
    Song HS; Do YR; Chang HM; Ryu MH; Lee KH; Kim YH; Hong DS; Cho JY; Lee KE; Kim SY
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):763-8. PubMed ID: 18172648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Xiao BY; Wang BC; Lin GH; Li PC
    Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
    Winther SB; Bjerregaard JK; Schonnemann KR; Ejlsmark MW; Krogh M; Jensen HA; Pfeiffer P
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):573-578. PubMed ID: 29387963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
    Stathopoulos GP; Syrigos K; Polyzos A; Fountzilas G; Rigatos SK; Ziras N; Potamiannou A; Tsiakopoulos I; Androulakis N; Aravantinos G; Athanasiadis A; Papakotoulas P; Georgoulias V
    Ann Oncol; 2004 Feb; 15(2):224-9. PubMed ID: 14760113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
    Johns C; Diaz CL; Hwang J; Kerridge WD; Ko AH; Tempero MA
    Pancreas; 2019 Aug; 48(7):927-930. PubMed ID: 31268983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Bernhard J; Dietrich D; Scheithauer W; Gerber D; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi BC; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Herrmann R;
    J Clin Oncol; 2008 Aug; 26(22):3695-701. PubMed ID: 18669454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.